NCT03602014View on ClinicalTrials.gov

Dose Response to the Norepinephrine Precursor Droxidopa in Hypotensive Individuals With Spinal Cord Injury

PHASE4CompletedINTERVENTIONAL
Enrollment

22

Participants

Timeline

Start Date

June 1, 2018

Primary Completion Date

December 31, 2021

Study Completion Date

December 31, 2021

Conditions
Hypotension, OrthostaticHypotensionSpinal Cord Injuries
Interventions
DRUG

Northera

Study 1 is a dose optimization, open-label trial of Northera from a dose range of 200mg up to 800mg.

OTHER

Placebo

Study 2 is blinded placebo controlled trial using the individualized optimal dose of droxidopa determined by study 1.

Trial Locations (2)

10029

The Icahn School of Medicine at Mount Sinai, New York

10468

James J. Peters Veteran's Affair Medical Center, The Bronx

All Listed Sponsors
collaborator

New York State Department of Health

OTHER_GOV

lead

James J. Peters Veterans Affairs Medical Center

FED

NCT03602014 - Dose Response to the Norepinephrine Precursor Droxidopa in Hypotensive Individuals With Spinal Cord Injury | Biotech Hunter | Biotech Hunter